| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2021. Refer to TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | chlormethine (Ledaga®) | |
| Formulation | 160 µg/g gel | |
| Reference number | 1566 | |
| Indication | Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients |
|
| Company | Actelion Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 12/07/2017 | |
| NICE guidance | TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma |
|